Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01667536 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology
A Phase 2 study, sponsored by Molecular Insight Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
NCT01667536 is a Phase 2 study that has completed, run by Molecular Insight Pharmaceuticals. The registered enrollment target is 105 participants.
The verdict
NCT01667536, a Phase 2 study, has completed, sponsored by Molecular Insight Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
Study Summary
This was a multicenter, multi-reader, open-label, Phase 2 study assessing the safety and performance characteristics of MIP 1404 imaging in the detection of prostate gland and pelvic lymph node cancer. Comparative performance characteristics between MIP 1404 imaging and MRI were also assessed, as judged by histopathology results.
Interventions
- DRUG Drug: 99mTc-MIP-1404
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2012-08 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01667536
The ClinicalTrials.gov registry entry for NCT01667536 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Molecular Insight Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Drug: 99mTc-MIP-1404 is the first listed.
NCT01667536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01667536 about?
NCT01667536 is a clinical study titled "A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology". This was a multicenter, multi-reader, open-label, Phase 2 study assessing the safety and performance characteristics of MIP 1404 imaging in the detection of prostate gland and pelvic lymph node cancer. Comparative performance characteristics between MIP 1404 imaging and MRI were also assessed, as ju...
What is the current status of trial NCT01667536?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2012-08. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01667536?
The interventions under investigation include: Drug: 99mTc-MIP-1404 (DRUG).
Who is sponsoring clinical trial NCT01667536?
This trial is sponsored by Molecular Insight Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.